Stephens Maintains Buy Rating and Raises Price Target for PacBio

Stephens analyst Mason Carrico has maintained a 'Buy' rating for Pacific Biosciences of California, Inc. (PacBio) and raised the price target from $2.00 to $2.50. This adjustment is based on the analyst's assessment of the company's stock performance and market position, as reported by the independent financial analysis platform TipRanks.